Your browser is no longer supported. Please, upgrade your browser.
Settings
ARCT [NASD]
Arcturus Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-7.52 Insider Own7.60% Shs Outstand26.34M Perf Week5.56%
Market Cap1.09B Forward P/E- EPS next Y-2.16 Insider Trans-28.80% Shs Float22.68M Perf Month-12.39%
Income-196.10M PEG- EPS next Q0.93 Inst Own68.60% Short Float8.94% Perf Quarter-29.63%
Sales8.80M P/S123.89 EPS this Y-65.00% Inst Trans-7.90% Short Ratio4.14 Perf Half Y36.52%
Book/sh9.84 P/B4.05 EPS next Y144.80% ROA-42.60% Target Price80.58 Perf Year-34.21%
Cash/sh15.14 P/C2.63 EPS next 5Y- ROE-59.70% 52W Range24.87 - 129.71 Perf YTD-8.05%
Dividend- P/FCF- EPS past 5Y10.80% ROI- 52W High-69.25% Beta2.68
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low60.39% ATR2.66
Employees118 Current Ratio3.60 Sales Q/Q4.30% Oper. Margin- RSI (14)50.00 Volatility6.54% 7.42%
OptionableYes Debt/Eq0.23 EPS Q/Q-124.30% Profit Margin- Rel Volume1.13 Prev Close36.01
ShortableYes LT Debt/Eq0.16 EarningsNov 08 AMC Payout- Avg Volume489.95K Price39.89
Recom2.90 SMA201.06% SMA50-8.92% SMA200-4.93% Volume552,381 Change10.77%
Aug-12-21Downgrade Raymond James Mkt Perform → Underperform
Aug-11-21Downgrade Goldman Neutral → Sell $29
Aug-10-21Downgrade Robert W. Baird Neutral → Underperform $31
Jul-02-21Initiated Cantor Fitzgerald Overweight $71
Jun-25-21Resumed Goldman Neutral $29
Jun-21-21Downgrade Barclays Equal Weight → Underweight $33 → $25
Jun-04-21Resumed Robert W. Baird Neutral $31
Feb-17-21Downgrade B. Riley Securities Neutral → Sell
Jan-19-21Downgrade B. Riley Securities Buy → Neutral $138 → $77
Jan-15-21Downgrade B. Riley Securities Buy → Neutral $138 → $77
Jan-07-21Initiated Wells Fargo Overweight $118
Dec-29-20Downgrade Robert W. Baird Outperform → Neutral $79 → $69
Dec-29-20Downgrade Raymond James Outperform → Mkt Perform
Dec-29-20Downgrade H.C. Wainwright Buy → Neutral
Dec-29-20Downgrade Barclays Overweight → Equal Weight $46
Dec-23-20Downgrade ROTH Capital Buy → Sell $77
Dec-08-20Reiterated B. Riley Securities Buy $111 → $138
Dec-07-20Reiterated B. Riley Securities Buy $64 → $111
Oct-26-20Initiated Barclays Overweight $72
Oct-06-20Initiated Citigroup Buy $65
Nov-22-21 08:00AM  
Nov-18-21 08:00PM  
Nov-10-21 04:20AM  
Nov-08-21 05:35PM  
04:00PM  
Nov-01-21 03:01PM  
Oct-25-21 04:00PM  
Oct-21-21 08:00AM  
Oct-20-21 08:00PM  
Oct-19-21 05:55AM  
Oct-18-21 10:01AM  
Oct-15-21 02:30AM  
Oct-12-21 08:00AM  
Sep-29-21 02:35PM  
Sep-22-21 04:01PM  
07:45AM  
07:00AM  
Sep-08-21 09:00AM  
Sep-07-21 09:00AM  
Sep-05-21 06:55AM  
Aug-11-21 01:00PM  
Aug-09-21 05:25PM  
04:01PM  
Aug-03-21 11:21AM  
07:00AM  
Aug-02-21 03:01PM  
11:22AM  
09:08AM  
09:00AM  
07:00AM  
Jul-28-21 08:30AM  
Jul-26-21 04:01PM  
Jul-06-21 09:00AM  
Jul-05-21 02:04AM  
Jun-09-21 09:00AM  
Jun-02-21 09:01AM  
May-21-21 02:24AM  
May-13-21 06:10AM  
May-10-21 08:05PM  
04:01PM  
02:30PM  
May-03-21 08:30AM  
Apr-29-21 05:02PM  
Apr-14-21 01:36AM  
Apr-05-21 06:15AM  
Mar-30-21 08:30AM  
Mar-09-21 06:35AM  
Mar-01-21 05:26PM  
04:01PM  
02:30PM  
Feb-28-21 02:14AM  
Feb-22-21 08:00AM  
Feb-19-21 08:00AM  
Feb-11-21 08:30AM  
Jan-28-21 08:30AM  
Jan-23-21 04:40AM  
Jan-12-21 06:51AM  
Jan-07-21 03:19PM  
Jan-06-21 03:59PM  
11:14AM  
08:00AM  
Jan-05-21 08:57AM  
07:27AM  
Jan-04-21 10:18AM  
07:22AM  
07:01AM  
Dec-31-20 07:32PM  
08:49AM  
Dec-30-20 12:34PM  
11:40AM  
11:22AM  
07:00AM  
Dec-29-20 11:02PM  
05:35PM  
05:11PM  
04:33PM  
04:23PM  
03:27PM  
11:42AM  
10:23AM  
09:59AM  
09:49AM  
08:09AM  
Dec-28-20 04:01PM  
Dec-23-20 11:23AM  
Dec-20-20 06:09AM  
Dec-19-20 10:10PM  
Dec-16-20 06:14AM  
Dec-13-20 02:02PM  
06:05AM  
Dec-12-20 07:03AM  
Dec-11-20 02:38PM  
06:45AM  
Dec-10-20 06:10AM  
Dec-08-20 06:20PM  
Dec-07-20 11:30PM  
11:18PM  
04:33PM  
07:00AM  
Dec-05-20 06:12AM  
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chivukula PadChief Scientific Officer & COONov 01Sale44.4110,000444,100612,548Nov 03 11:20 AM
Chivukula PadChief Scientific Officer & COOOct 01Sale44.3610,000443,600622,548Oct 04 05:01 PM
Chivukula PadChief Scientific Officer & COOSep 01Sale55.8610,000558,600632,548Sep 02 09:06 PM
Ultragenyx Pharmaceutical Inc.DirectorAug 11Sale45.8375,0003,437,2501,400,000Aug 12 05:11 PM
Ultragenyx Pharmaceutical Inc.DirectorAug 10Sale55.44725,00040,194,0001,475,000Aug 12 05:11 PM
Chivukula PadChief Scientific Officer & COOAug 03Sale40.0710,000400,700642,548Aug 05 04:32 PM
Chivukula PadChief Scientific Officer & COOApr 01Sale42.9510,000429,500652,548Apr 05 04:30 PM
Chivukula PadChief Scientific Officer & COOMar 01Sale54.2310,000542,300662,548Mar 03 04:30 PM
Chivukula PadChief Scientific Officer & COOFeb 01Sale75.3110,000753,100672,548Feb 03 04:45 PM
Chivukula PadChief Scientific Officer & COOJan 04Sale46.4010,000464,000682,548Jan 05 06:19 PM
Ultragenyx Pharmaceutical Inc.DirectorDec 09Sale94.97357,74533,975,0432,200,000Dec 10 04:55 PM
Ultragenyx Pharmaceutical Inc.DirectorDec 08Sale105.54442,25546,675,5932,557,745Dec 10 04:55 PM
Chivukula PadChief Scientific Officer & COODec 01Sale96.1910,000961,900692,548Dec 03 05:45 PM